Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024
05 9월 2024 - 3:00PM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”)
announces one oral presentation and 3 posters on additional
analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre
(ensifentrine) for the treatment of chronic obstructive pulmonary
disease (“COPD”) will be presented at the European Respiratory
Society (“ERS”) International Congress 2024. The abstracts are
available to conference participants on the ERS website and will be
published in an upcoming issue of the peer reviewed publication,
European Respiratory Journal.
Ohtuvayre (ensifentrine) is a first-in-class
selective dual inhibitor of the enzymes phosphodiesterase 3 and
phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator
and non-steroidal anti-inflammatory effects in one molecule. The
therapy is the first novel inhaled mechanism for the maintenance
treatment of COPD in more than 20 years.
The analyses will summarize the efficacy and
safety of Ohtuvayre in the subgroup of patients, including
reduction in the rate of exacerbation, with or without chronic
bronchitis and in European patients. Additionally, a pooled
analysis of patient reported outcomes and the effect of Ohtuvayre
on reducing cough and sputum will also be presented.
“These analyses provide further support for
Ohtuvayre’s potential to benefit a broad population of patients
with COPD,” said Jadwiga Wedzicha, MD, Professor of Respiratory
Medicine at the National Heart and Lung Institute, Imperial College
London, UK. “The non-steroidal anti-inflammatory effects with this
novel therapy are particularly beneficial and I am very excited
about the impact of Ohtuvayre on COPD.”
Details of Verona Pharma’s presentations and
posters are listed below and linked to the ERS website:
Oral presentation 2780:
Ensifentrine improved lung function and reduced moderate/severe
exacerbation rate and risk in patients with COPD regardless of
chronic bronchitis historyParticipant: Jadwiga
Wedzicha, MD, Professor of Respiratory Medicine at the National
Heart and Lung Institute, Imperial College London,
UKSession 265: Airway diseases therapeutics: novel
research studies
Poster 2991: Ensifentrine
treatment improves COPD symptoms and quality of life in a pooled
analysis of the ENHANCE trialsParticipant:
Alexander Mathioudakis, MD, NIHR Clinical Lecturer in Respiratory
Medicine, University of Manchester, UKSession 300:
New frontiers in chronic obstructive pulmonary disease treatment
and management
Poster 2995: Efficacy and
safety of ensifentrine in European patients with moderate to severe
COPD: pooled results from the ENHANCE
trialsParticipant: Frits M.E. Franssen, MD, Head
of the Department of Respiratory Medicine, Maastricht University
Medical Center, The NetherlandsSession 300: New
frontiers in chronic obstructive pulmonary disease treatment and
management
Poster 2997: Ensifentrine
improved symptoms and reduced moderate/severe exacerbation rate and
risk in patients with COPD and significant cough and
sputumParticipant: Victor Kim, MD, Professor,
Thoracic Medicine and Surgery, Lewis Katz School of Medicine at
Temple University, USSession 300: New frontiers in
chronic obstructive pulmonary disease treatment and management
For further information please contact:
|
|
Verona Pharma plc |
Tel: +1-844-341-9901 |
Victoria Stewart, Senior Director of Investor Relations and
Communications |
IR@veronapharma.com |
Argot Partners(US Investor Enquiries) |
Tel: +1-212-600-1902verona@argotpartners.com |
Ten Bridge CommunicationsInternational / US Media
Enquiries |
Tel: +1-312-523-5016tbcverona@tenbridgecommunications.com |
Leslie Humbel |
|
About Ohtuvayre
(ensifentrine)
Ohtuvayre is the first inhaled therapy for the
maintenance treatment of COPD that combines bronchodilator and
non-steroidal anti-inflammatory activities in one molecule. Verona
has evaluated nebulized Ohtuvayre in its Phase 3 clinical program
ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”)
for COPD maintenance treatment. Ohtuvayre met the primary endpoint
in both ENHANCE-1 and ENHANCE-2, demonstrating statistically
significant and clinically meaningful improvements in lung
function. A fixed-dose combination of ensifentrine and
glycopyrrolate, a LAMA, is currently under development for the
maintenance treatment of COPD.
About Verona Pharma
Verona Pharma is a biopharmaceutical company
focused on developing and commercializing innovative therapies for
the treatment of chronic respiratory diseases with significant
unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s
first commercial product and the first inhaled therapy for the
maintenance treatment of COPD that combines bronchodilator and
non-steroidal anti-inflammatory activities in one molecule.
Ensifentrine has potential applications in non-cystic fibrosis
bronchiectasis, cystic fibrosis, asthma and other respiratory
diseases. For more information, please
visit www.veronapharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended. All statements contained in this
press release other than statements of historical fact should be
considered forward-looking statements. Words such as “anticipate,”
“believe,” “plan,” “expect,” “intend,” “may,” “potential,”
“prepare,” “possible” and similar words and expressions are
intended to identify forward-looking statements. These
forward-looking statements include, but are not limited to,
statements regarding the potential benefits and efficacy of our
drug Ohtuvayre and future poster presentations and academic
publications pertaining to Ohtuvayre.
These forward-looking statements are based on
management's current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from our expectations expressed or implied by the forward-looking
statements, including, but not limited to, the efficacy of
Ohtuvayre compared to competing drugs and the other important
factors discussed under the caption “Risk Factors” in our Quarterly
Report on Form 10-Q for the period ended June 30, 2024 filed with
the Securities and Exchange Commission (“SEC”) on August 8, 2024,
as such factors may be updated from time to time in our other
filings with the SEC. We disclaim any obligation to update or
revise any forward-looking statement contained in this press
release, even if subsequent events cause our views to change,
except as required under applicable law.
Verona Pharma (NASDAQ:VRNA)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Verona Pharma (NASDAQ:VRNA)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024